Protagonist Therapeutics (PTGX) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 42.2% versus a gain of 10.4%. Over five years, RYTM leads with a +1116.0% price change compared with +265.0% for PTGX. Protagonist Therapeutics is the larger company by market cap ($7.92 billion vs $7.79 billion), about 1.0 times the size, while Rhythm Pharmaceuticals is growing revenue faster (+45.8% vs -89.4%).
Rhythm Pharmaceuticals converts more of its revenue into profit, with a net margin of -103.6% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTGX | RYTM |
|---|---|---|
| Share price | $121.40 | $112.36 |
| Market cap | $7.92B | $7.79B |
| 1-day change | -2.11% | -3.80% |
| YTD return | +39.00% | +4.97% |
| 1-year return | +42.15% | +10.44% |
| 5-year return | +265.00% | +1116.02% |
| P/E ratio (TTM) | 25.67 | — |
| Forward P/E | 348.79 | — |
| EPS (TTM) | $4.73 | $-2.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $46.02M | $189.76M |
| Revenue growth (YoY) | -89.41% | +45.83% |
| Net income (latest FY) | $-130.15M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | -343.63% | -101.19% |
| Net margin | -282.83% | -103.57% |
| 52-week high | $160.81 | $122.20 |
| 52-week low | $77.00 | $74.50 |
| Distance from 52-week high | -24.51% | -8.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +50.21% | +24.71% |
| Average volume | 668.45K | 1.10M |
| Shares outstanding | 65.27M | 69.33M |
| Employees | 149 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed RYTM by 31.7 percentage points over the past year.
- Rhythm Pharmaceuticals is more profitable, keeping -103.6 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Rhythm Pharmaceuticals grew revenue faster in its latest fiscal year (+45.83% vs -89.41%).
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
PTGX vs RYTM FAQ
Which is bigger, Protagonist Therapeutics or Rhythm Pharmaceuticals?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $7.92B compared with $7.79B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, PTGX or RYTM?
PTGX returned +42.15% over the past 12 months, compared with +10.44% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Protagonist Therapeutics and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.